Latest Executive Appointments News

Synertec Corporation reported resilience in FY25 despite sector headwinds, with a strong rebound in engineering profits and a 90% revenue jump in its renewable Powerhouse technology.

Nufarm Limited has announced Rico Christensen as its new CEO, effective January 2026, succeeding Greg Hunt who will stay on as advisor until mid-2026. Christensen brings three decades of global agricultural sector expertise and a strong operational focus.

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Golden State Mining has appointed Keith Middleton as Managing Director and CEO, bringing over two decades of mining sector expertise and a strategic vision for growth. His leadership comes with a significant share-based incentive, signaling a new chapter for the exploration company.

Mount Ridley Mines has appointed Allister Caird as CEO, bringing critical minerals expertise to accelerate its rare earth and gallium projects in Western Australia and expand US partnerships.

Gateway Mining has completed its acquisition of the Yandal Gold Project, revealing promising high-grade gold results and securing $22.5 million to fuel extensive exploration and drilling programs.

Thunderbird Resources has executed a binding agreement to acquire 100% of the Springfield Gold Deposit in NSW, an advanced project with significant high-grade gold mineralisation. The company also raised $2.2 million to fund exploration and appointed new senior executives to drive growth.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

Astral Resources reports robust exploration results across its Western Australian gold projects and key progress on the Mandilla Definitive Feasibility Study, alongside a new joint venture at the Think Big deposit.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

L1 Group has appointed Julian Russell as its new CEO and Managing Director, marking a strategic leadership transition aimed at capitalising on growth opportunities. Russell’s proven track record in financial services turnaround sets the stage for renewed momentum.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.